U.S. Veterinary Oncology Market Size, Share & Trends Analysis Report By Therapy (Surgery, Radiology, Chemotherapy, Immunotherapy), By Animal Type (Canine, Feline), And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation And Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4. Information/Data Analysis
1.4.1 Information Analysis
1.5. Market Formulation & Visualization
1.6. Data Validation & Publishing
1.7. Model Details
1.8. List Of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Insights Snapshot
Chapter 3. U.S. Veterinary Oncology Market Variables, Trends, and Scope
3.1. Market Lineage
3.1.1. Parent Market Analysis
3.1.2. Ancillary Market Analysis
3.2. U.S. Veterinary Oncology Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing prevalence of cancer in pets
3.2.1.2. Increasing R&D in pet cancer therapy
3.2.1.3. Growing focus on animal safety
3.2.1.4. Growing demand for pet insurance
3.2.1.5. Technological advancements in pet cancer treatment
3.2.1.6. Increase in pet adoption
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of pet cancer treatments
3.2.2.2. Increasing incidence of pet abandonment and euthanasia
3.2.2.3. Adverse effects of drugs used for pet cancer treatment
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenges Analysis
3.3. U.S. Veterinary Oncology Market: Porter’s 5 Forces Analysis
3.3.1.1. Threat of New Entrants
3.3.1.2. Threat of Substitutes
3.3.1.3. Bargaining Power of Buyers
3.3.1.4.供应商讨价还价的能力
3.3.1.5. Competitive Rivalry
3.4. U.S. Veterinary Oncology Market: PESTLE Analysis
3.4.1.1. Political Landscape
3.4.1.2. Economic Landscape
3.4.1.3. Social Landscape
3.4.1.4. Technology Landscape
3.4.1.5. Legal Landscape
3.4.1.6. Environmental Landscape
3.5. User Perspective Analysis
3.6. Regulatory Framework
3.7. Technology Overview
3.8. Therapy Pipeline Analysis
3.9. Pricing Analysis
3.10. Covid-19 Impact Analysis
3.11. Estimated pet population by key species, 2018 to 2022
Chapter 4. Therapy Estimates & Trend Analysis, 2018 – 2030 (USD Million)
4.1. U.S. Veterinary Oncology Market By Therapy: Key Takeaways
4.2. Therapy Movement Analysis & Market Share, 2022 & 2030
4.3. U.S. Veterinary Oncology Market Estimates & Forecast, By Therapy (USD Million)
4.4. Surgery
4.4.1. Surgery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5. Radiology
4.5.1.放射学市场估计和预测,2018 - 2030 (USD Million)
4.5.2. Stereotactic Radiation Therapy
4.5.2.1. Stereotactic Radiation Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2.2. Gamma knife
4.5.2.2.1. Gamma knife Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2.3. Linear accelerators
4.5.2.3.1. Linear accelerators Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2.4. Particle beam
4.5.2.4.1. Particle beam Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.2.5. Cyberknife
4.5.2.5.1. Cyberknife Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.3. Brachytherapy
4.5.3.1. Brachytherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.5.4. Others
4.5.4.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.6. Chemotherapy
4.6.1. Chemotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.7. Immunotherapy
4.7.1. Immunotherapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Animal Type Estimates & Trend Analysis, 2018 – 2030 (USD Million)
5.1. U.S. Veterinary Oncology Market By Animal Type: Key Takeaways
5.2. Animal Type Movement Analysis & Market Share, 2022 & 2030
5.3. U.S. Veterinary Oncology Market Estimates & Forecast, By Animal Type (USD Million)
5.4. Canine
5.4.1. Canine Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.2. Lymphoma
5.4.2.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.3. Mast Cell Cancer
5.4.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.4. Mammary and Squamous Cell Cancer
5.4.4.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.5. Others
5.4.5.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5. Feline
5.5.1. Feline Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.2. Mammary and Squamous Cell Cancer
5.5.2.1. Mammary and Squamous Cell Cancer Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.3. Others
5.5.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Key Company Profiles
• Zoetis
• Boehringer Ingelheim International GmbH
• Elanco
• PetCure Oncology
• Accuray Incorporated
• Varian Medical Systems, Inc.
• Morphogenesis, Inc.
• Karyopharm Therapeutics, Inc.
• Regeneus Ltd.
• OHC (One Health Company)
6.2.1. Participant’s Overview
6.2.2. Therapy Benchmarking
6.2.3. Financial Performance
6.2.4. Strategy Mapping
6.3. List Of Key Companies
6.4. Company Market Position Analysis

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviation
Table 3 U.S. Pet Ownership
Table 4 U.S. Pet Expenditure
Table 5 U.S. Veterinary Oncology Market, by therapy, 2018 - 2030 (USD Million)
Table 6 U.S. Veterinary radiology Market, by type, 2018 - 2030 (USD Million)
Table 7 U.S. Veterinary stereotactic radiation therapy Market, by type, 2018 - 2030 (USD Million)
Table 8 U.S. Veterinary Oncology Market, by animal type, 2018 - 2030 (USD Million)
Table 9 U.S. feline oncology Market by cancer type, 2018 - 2030 (USD Million)
Table 10 U.S. canine oncology Market by cancer type, 2018 - 2030 (USD Million)
Table 11 Company Overview
Table 12 Financial Performance
Table 13 Therapy Benchmarking
Table 14 Strategic Initiatives

List of Figures

Fig.1 Market segmentation
Fig.2 Market research process
Fig.3 Data triangulation techniques
Fig.4 Primary research pattern
Fig.5 Market research approaches
Fig.6 Value-chain-based sizing & forecasting
Fig.7 QFD modeling for market share assessment
Fig.8 Market formulation & validation
Fig.9母公司的市场分析
Fig.10 Commodity flow analysis
Fig.11 Market snapshot
Fig.12 Segment snapshot
Fig.13 Competitive landscape snapshot
Fig.14 U.S. Veterinary Oncology Market Dynamics
Fig.15 U.S. Veterinary Oncology Market: PORTER’s Analysis
Fig.16 U.S. Veterinary Oncology Market PESTLE Analysis
Fig.17 U.S. Veterinary Oncology Market: Therapy movement analysis
Fig.18 U.S. Veterinary Oncology Market: Therapy Key takeaways
Fig.19 Global Surgery market 2018 - 2030 (USD Million)
Fig.20 Global Radiology market 2018 - 2030 (USD Million)
Fig.21 Global Stereotactic Radiation Therapy market 2018 - 2030 (USD Million)
Fig.22 Global Gamma knife market 2018 - 2030 (USD Million)
Fig.23 Global Linear accelerators market 2018 - 2030 (USD Million)
Fig.24 Global Particle beam market 2018 - 2030 (USD Million)
Fig.25 Global Cyberknife market 2018 - 2030 (USD Million)
Fig.26 Global Brachytherapy market 2018 - 2030 (USD Million)
Fig.27 Global Others market 2018 - 2030 (USD Million)
Fig.28 Global Chemotherapy market 2018 - 2030 (USD Million)
Fig.29 Global Immunotherapy market 2018 - 2030 (USD Million)
Fig.30 Global Others market 2018 - 2030 (USD Million)
Fig.31 U.S. Veterinary Oncology Market: Animal Type movement analysis
Fig.32 U.S. Veterinary Oncology Market: Animal Type Key takeaways
Fig.33 Global Canine market 2018 - 2030 (USD Million)
Fig.34 Global Canine Lymphoma market 2018 - 2030 (USD Million)
Fig.35 Global Canine Mast Cell Cancer market 2018 - 2030 (USD Million)
Fig.36 Global Canine Mammary and Squamous Cell Cancer market 2018 - 2030 (USD Million)
Fig.37 Global Canine Others market 2018 - 2030 (USD Million)
Fig.38 Global Feline market 2018 - 2030 (USD Million)
Fig.39 Global Feline Mammary and Squamous Cell Cancer market 2018 - 2030 (USD Million)
Fig.40 Global Feline Others market 2018 - 2030 (USD Million)
Fig.41 Global Other market 2018 - 2030 (USD Million)
Fig.42 List of secondary sources